EDGEWISE THERAPEUTICS INC (EWTX) Stock Analyst Earnings Estimates
NASDAQ:EWTX - Nasdaq - US28036F1057 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 863.62% | N/A 235.85% | N/A 119.14% | N/A 87.75% | N/A 52.26% | N/A 48.28% | ||||||
| EBITDA YoY % growth | -9.8M | -17M -73.47% | -42.95M -152.65% | -71.29M -65.98% | -112.806M -58.24% | N/A -38.67% | N/A -20.09% | N/A -21.69% | N/A 10.70% | N/A 100.45% | N/A 45,742.31% | N/A 147.33% | N/A 60.17% | N/A 49.25% | |
| EBIT YoY % growth | -9.92M | -17.19M -73.29% | -43.22M -151.43% | -71.66M -65.80% | -114.357M -59.58% | N/A -37.57% | N/A -28.54% | N/A -16.66% | N/A -9.72% | N/A 70.15% | N/A 339.19% | N/A 200.11% | N/A 75.47% | N/A 60.41% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -0.87 | -1.27 -45.98% | -1.58 -24.41% | N/A 3.49% | N/A -22.32% | N/A -14.52% | N/A -19.13% | N/A 78.36% | N/A 466.67% | N/A 184.01% | N/A 50.98% | N/A 54.93% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.40 14.74% | -0.39 -16.84% | -0.42 -24.80% | -0.46 -27.50% | -0.49 -23.45% | -0.53 -37.57% | -0.54 -27.40% | -0.57 -24.44% | -0.60 -21.65% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | |||||
| EBITDA Q2Q % growth | -41.786M -29.33% | -43.254M -26.18% | -45.774M -23.20% | -51.352M -31.87% | -54.378M -30.13% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -42.877M -26.62% | -43.795M -26.02% | -46.625M -22.35% | -50.537M -24.99% | -55.639M -29.76% | -56.814M -29.73% | -57.883M -24.15% | -60.957M -20.62% | -63.773M -14.62% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.36 12.20% | -0.38 | 0.02 | 4.98% |
| Q2 2024 Q2Q % growth | -0.34 | -0.35 | 0.01 | 3.18% |
| Q1 2024 Q2Q % growth | -0.33 8.33% | -0.40 | 0.07 | 17.47% |
| Q4 2023 Q2Q % growth | -0.47 -51.61% | -0.44 | -0.03 | -6.17% |
| Q3 2023 Q2Q % growth | -0.41 -20.59% | -0.40 | -0.01 | -1.51% |
| Q2 2023 Q2Q % growth | -0.34 -6.25% | -0.41 | 0.07 | 16.25% |
| Q1 2023 Q2Q % growth | -0.36 -20.00% | -0.37 | 0.01 | 1.96% |
| Q4 2022 Q2Q % growth | -0.31 -19.23% | -0.34 | 0.03 | 9.55% |
| Q3 2022 Q2Q % growth | -0.34 -30.77% | -0.36 | 0.02 | 6.37% |
| Q2 2022 Q2Q % growth | -0.32 -52.38% | -0.33 | 0.01 | 3.17% |
| Q1 2022 Q2Q % growth | -0.30 -114.29% | -0.28 | -0.02 | -5.80% |
| Q4 2021 Q2Q % growth | -0.26 | -0.25 | -0.01 | -2.99% |
| Q3 2021 Q2Q % growth | -0.26 | -0.23 | -0.03 | -14.14% |
| Q2 2021 Q2Q % growth | -0.21 | -0.18 | -0.03 | -15.99% |
| Q1 2021 Q2Q % growth | -0.14 | -0.16 | 0.02 | 12.85% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 0.36% | 0% | -0.24% |
| Revenue | N/A | N/A | N/A | N/A |